Sugi Predict

Sugi Predict / Compounds / SCHEMBL571098

SCHEMBL571098

SCHEMBL571098

C=C1CC(NC(=O)OC(C)(C)C)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.50
▸ GAA P10253 2/20 0.49
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ CTSK P43235 2/20 0.46
▸ KDM1A O60341 2/20 0.43
▸ MAOB P27338 1/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ EPHX1 P07099 1/20 0.41
▸ KCNA3 P22001 1/20 0.40
▸ CYP2C9 P11712 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509416 0.84 BTK (0.50) BTKGAANFKB1NFKB2RELA
SCHEMBL15542249 0.83 BTK (0.54) BTKGAANFKB1NFKB2RELA
SCHEMBL16653735 0.83 BTK (0.54) BTKGAANFKB1NFKB2RELA
SCHEMBL16520179 0.83 BTK (0.54) BTKGAANFKB1NFKB2RELA
SCHEMBL8222638 0.83 GAA (0.49) BTKGAANFKB1NFKB2RELA
SCHEMBL570801 0.82 GAA (0.54) BTKGAANFKB1NFKB2RELA
Water SCHEMBL17140922 0.82 CTSK (0.49) BTKGAANFKB1NFKB2RELA
SCHEMBL12420583 0.81 NFKB1 (0.45) BTKGAANFKB1NFKB2RELA
SCHEMBL25568464 0.80 BTK (0.43) BTKGAANFKB1NFKB2RELA
SCHEMBL3702152 0.79 BTK (0.61) BTKGAANFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024129763-A1 MODULATORS OF TNF-α ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2024-06-20 — — WO disclosed
CN-115785084-B Pyrimidine derivatives and their use in medicine 广东东阳光药业股份有限公司 2024-01-16 — — CN disclosed
CN-115785084-A Pyrimidine derivatives and their use in medicine 广东东阳光药业有限公司 2023-03-14 — — CN disclosed
US-11479546-B2 Antimalarial hexahydropyrimidine analogues UCB Biopharma SRL 2022-10-25 — — US disclosed
EP-3774741-B1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES UCB Biopharma SRL (BE) 2022-06-08 — — EP disclosed
EP-3390384-B1 QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2021-09-15 — — EP disclosed
US-11117915-B2 Antibacterial aminoglycoside analogs Cipla USA, Inc. (US) 2021-09-14 — — US disclosed
US-11117915-B2 Antibacterial aminoglycoside analogs Cipla USA, Inc. (US) 2021-09-14 — — US disclosed
US-20210238162-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-08-05 — — US disclosed
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-07-06 — — US disclosed
EP-2148884-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS Achaogen, Inc. (US) 2010-02-03 — — EP disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 — — WO disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 — — WO disclosed
US-7511062-B2 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors SCHERING CORPORATION (US) 2009-03-31 — — US disclosed
US-7511062-B2 Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors SCHERING CORPORATION (US) 2009-03-31 — — US disclosed
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-12-04 — — US disclosed
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-12-04 — — US disclosed
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-12-04 — — US disclosed
WO-2008124821-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-10-16 — — WO disclosed
WO-2008124821-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ACHAOGEN INC. (US) 2008-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479546-B2 Antimalarial hexahydropyrimidine analogues G6PD, DPYD, DHODH BTK 2336/4885GAA 3464/4885NFKB1 3697/4885
US-11053234-B2 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors HPGDS, PTGDR, PTGER1 BTK 3851/4885GAA 568/4885NFKB1 1936/4885
US-20080300199-A1 ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS ALG8, NRDC, MRPL21 BTK 2828/4885GAA 100/4885NFKB1 485/4885
US-20210238162-A1 CHEMICAL COMPOUNDS HPGDS, PTGS1, PTGIS BTK 4035/4885GAA 550/4885NFKB1 2264/4885
US-11117915-B2 Antibacterial aminoglycoside analogs MRPL21, MRPL9, NQO2 BTK 2661/4885GAA 253/4885NFKB1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.